Table 6. Univariate Analysis of Survival – Intrahepatic CCA.

RISK FACTOR	MEDIAN PFS (Months)	p-value	95% CI	MEDIAN OS (Months)	p-value	95% CI
Clinical Stage
Stage II	20.5	0.0172	4.0 – NA	NA	0.01868	NA – NA
Stage III	15.6		3.8 – NA	40.2		9.4 – NA
Stage IV	6.0		3.9–10.1	12.3		8.1 - NA
Surgery
No	7.3	0.9968	5.0 – NA	12.3	0.0291	8.1 – NA
Yes	6.0		3.9 - NA	NA		19.5 - NA
Radiation
No	7.1	0.6752	4.9 – NA	19.5		10.4 – NA
Yes	6.3		3.0 – NA	40.2	0.51	7.4 - NA
Gender
Female	10.1	0.09115	5.0–20.5	40.2	0.00329	20.7 – NA
Male	4.9		3.2 – NA	7.4		6.8 - NA
Ethnicity
Asian	5.3	0.7377	4.6 – NA	9.0	0.9659	9.0 – NA
Black	7.3		1.8 – NA	17.7		12.3 – NA
Hispanic	7.7		7.1 – NA	15.6		6.8 – NA
White	6.3		4.0 – 19.4	20.7		9.4 - NA
TP53
No	7.7	0.5145	6.0–16.5	66.5	0.0005	17.6 – NA
Yes	4.9		3.1 – NA	6.6		4.6 - NA
KRAS
No	10.1	0.01032	6.1–20.5	40.2	0.002588	19.5 – NA
Yes	3.4		3.0 – NA	7.4		6.1 – NA
ARID1A
No	7.1	0.5642	4.2–16.5	19.5	0.7588	9.4 – NA
Yes	14.6		5.0 – NA	40.2		7.3 – NA
ERBB2
No	7.1	0.4102	4.6–15.6	20.7	0.09627	12.3 – NA
Yes	NA		NA – NA	6.6		NA – NA
PBRM1
No	7.7	0.1523	4.9–16.5	20.7	0.4427	12.3 – NA
Yes	4.8		3.3 – NA	9.4		9.0 – NA
BAP1
No	6.3	0.363	2.9–9.7	20.7	0.746	2.7 – 38.7
Yes	7.1		0–15.2	10.4		4.3–16.5
FBXW7
No	7.3		5.0–16.5	20.7		12.3 – NA
Yes	3.8		3.0 – NA	6.1		4.6 – NA
SMAD4
No	7.1		4.9–15.6	20.7		12.3 – NA
Yes	3.8		NA – NA	3.2		1.7 – NA
MAP/ERK Pathway
No	10.1	0.003578	6.3–25.6	40.2	0.01961	19.5 – NA
Yes	3.9		3.0–14.0	8.6		6.8 – NA
mTOR Pathway
No	7.7	0.4728	5.0–19.4	66.5	0.0373	12.3 – NA
Yes	4.6		3.8 – NA	12.1		7.3 – NA
DNA Repair Pathway
No	7.7	0.741	4.6–16.5	20.7	0.527	12.3 – NA
Yes	6.1		3.3 – NA	10.4		9.4 – NA
FGF Pathway
No	3.1	0.2031	4.0–16.5	17.6	0.00973	9.0 – NA
Yes	14.0		6.3 – NA	NA		NA – NA
Chromatin modification Pathway
No	7.3	0.5492	4.2–19.4	19.5	0.8472	8.6 – NA
Yes	6.1		3.3 – NA	40.2		9.4 – NA